Cell Therapeutics (NASDAQ: CTIC), the Seattle-based developer of cancer drugs, said today in a regulatory filing that it lost an arbitration dispute with Irvine, CA-based Spectrum Pharmaceuticals worth $4.3 million. In February, CTI sold its remaining stake in the lymphoma drug ibritumomab tiuxetan (Zevalin) to Spectrum for $16.5 million. In April, Spectrum refused to pay a final installment payment of $3.5 million, saying CTI owed it that amount and more. The arbitrator agreed, allowing Spectrum to keep the $3.5 million, and ordering CTI to pay Spectrum another $776,000.
By posting a comment, you agree to our terms and conditions.